Vical moves SARS vaccine at unprecedented speed into the clinic

 
• By John Davis

The US firm Vical has shown that innovation is still alive and kicking in the industry – Phase I data on its potential SARS vaccine has been published only 19 months after the release of the genetic sequence of the coronavirus responsible for severe acute respiratory syndrome.

The US firm Vical has shown that innovation is still alive and kicking in the industry – Phase I data on its potential SARS vaccine has been published only 19 months after the release of the genetic sequence of the coronavirus responsible for severe acute respiratory syndrome.

The results of the Phase I study of the vaccine, conducted at the US National Institutes of Health, were published...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapeutic Category

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.